Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

A new genetically engineered mouse model of choroid plexus carcinoma.

El Nagar S, Zindy F, Moens C, Martin L, Plassard D, Roussel MF, Lamonerie T, Billon N.

Biochem Biophys Res Commun. 2018 Feb 5;496(2):568-574. doi: 10.1016/j.bbrc.2017.11.192. Epub 2018 Jan 12.

2.

Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells.

Kawauchi D, Ogg RJ, Liu L, Shih DJH, Finkelstein D, Murphy BL, Rehg JE, Korshunov A, Calabrese C, Zindy F, Phoenix T, Kawaguchi Y, Gronych J, Gilbertson RJ, Lichter P, Gajjar A, Kool M, Northcott PA, Pfister SM, Roussel MF.

Oncogene. 2017 Sep 14;36(37):5231-5242. doi: 10.1038/onc.2017.110. Epub 2017 May 15.

3.

Dicer Is Required for Normal Cerebellar Development and to Restrain Medulloblastoma Formation.

Zindy F, Lee Y, Kawauchi D, Ayrault O, Merzoug LB, Li Y, McKinnon PJ, Roussel MF.

PLoS One. 2015 Jun 19;10(6):e0129642. doi: 10.1371/journal.pone.0129642. eCollection 2015.

4.

Generation of Atoh1-rtTA transgenic mice: a tool for inducible gene expression in hair cells of the inner ear.

Cox BC, Dearman JA, Brancheck J, Zindy F, Roussel MF, Zuo J.

Sci Rep. 2014 Nov 3;4:6885. doi: 10.1038/srep06885.

5.

Role of the miR-17∼92 cluster family in cerebellar and medulloblastoma development.

Zindy F, Kawauchi D, Lee Y, Ayrault O, Ben Merzoug L, McKinnon PJ, Ventura A, Roussel MF.

Biol Open. 2014 Jun 13;3(7):597-605. doi: 10.1242/bio.20146734.

6.

Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma.

Morfouace M, Shelat A, Jacus M, Freeman BB 3rd, Turner D, Robinson S, Zindy F, Wang YD, Finkelstein D, Ayrault O, Bihannic L, Puget S, Li XN, Olson JM, Robinson GW, Guy RK, Stewart CF, Gajjar A, Roussel MF.

Cancer Cell. 2014 Apr 14;25(4):516-29. doi: 10.1016/j.ccr.2014.02.009. Epub 2014 Mar 27.

7.

Silencing of the miR-17~92 cluster family inhibits medulloblastoma progression.

Murphy BL, Obad S, Bihannic L, Ayrault O, Zindy F, Kauppinen S, Roussel MF.

Cancer Res. 2013 Dec 1;73(23):7068-78. doi: 10.1158/0008-5472.CAN-13-0927. Epub 2013 Oct 21.

8.

Age-dependent in vivo conversion of mouse cochlear pillar and Deiters' cells to immature hair cells by Atoh1 ectopic expression.

Liu Z, Dearman JA, Cox BC, Walters BJ, Zhang L, Ayrault O, Zindy F, Gan L, Roussel MF, Zuo J.

J Neurosci. 2012 May 9;32(19):6600-10. doi: 10.1523/JNEUROSCI.0818-12.2012.

9.

Roles of p53 and p27(Kip1) in the regulation of neurogenesis in the murine adult subventricular zone.

Gil-Perotin S, Haines JD, Kaur J, Marin-Husstege M, Spinetta MJ, Kim KH, Duran-Moreno M, Schallert T, Zindy F, Roussel MF, Garcia-Verdugo JM, Casaccia P.

Eur J Neurosci. 2011 Oct;34(7):1040-52. doi: 10.1111/j.1460-9568.2011.07836.x. Epub 2011 Sep 7.

10.

Subtypes of medulloblastoma have distinct developmental origins.

Gibson P, Tong Y, Robinson G, Thompson MC, Currle DS, Eden C, Kranenburg TA, Hogg T, Poppleton H, Martin J, Finkelstein D, Pounds S, Weiss A, Patay Z, Scoggins M, Ogg R, Pei Y, Yang ZJ, Brun S, Lee Y, Zindy F, Lindsey JC, Taketo MM, Boop FA, Sanford RA, Gajjar A, Clifford SC, Roussel MF, McKinnon PJ, Gutmann DH, Ellison DW, Wechsler-Reya R, Gilbertson RJ.

Nature. 2010 Dec 23;468(7327):1095-9. doi: 10.1038/nature09587. Epub 2010 Dec 8.

11.

Atoh1 inhibits neuronal differentiation and collaborates with Gli1 to generate medulloblastoma-initiating cells.

Ayrault O, Zhao H, Zindy F, Qu C, Sherr CJ, Roussel MF.

Cancer Res. 2010 Jul 1;70(13):5618-27. doi: 10.1158/0008-5472.CAN-09-3740. Epub 2010 Jun 1.

12.

Inhibition of Hsp90 via 17-DMAG induces apoptosis in a p53-dependent manner to prevent medulloblastoma.

Ayrault O, Godeny MD, Dillon C, Zindy F, Fitzgerald P, Roussel MF, Beere HM.

Proc Natl Acad Sci U S A. 2009 Oct 6;106(40):17037-42. doi: 10.1073/pnas.0902880106. Epub 2009 Sep 23.

13.

Transient expression of the Arf tumor suppressor during male germ cell and eye development in Arf-Cre reporter mice.

Gromley A, Churchman ML, Zindy F, Sherr CJ.

Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6285-90. doi: 10.1073/pnas.0902310106. Epub 2009 Apr 1. Erratum in: Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):9120.

14.

Two tumor suppressors, p27Kip1 and patched-1, collaborate to prevent medulloblastoma.

Ayrault O, Zindy F, Rehg J, Sherr CJ, Roussel MF.

Mol Cancer Res. 2009 Jan;7(1):33-40. doi: 10.1158/1541-7786.MCR-08-0369.

15.

Post-transcriptional down-regulation of Atoh1/Math1 by bone morphogenic proteins suppresses medulloblastoma development.

Zhao H, Ayrault O, Zindy F, Kim JH, Roussel MF.

Genes Dev. 2008 Mar 15;22(6):722-7. doi: 10.1101/gad.1636408.

16.

N-myc coordinates retinal growth with eye size during mouse development.

Martins RA, Zindy F, Donovan S, Zhang J, Pounds S, Wey A, Knoepfler PS, Eisenman RN, Roussel MF, Dyer MA.

Genes Dev. 2008 Jan 15;22(2):179-93. doi: 10.1101/gad.1608008.

17.

[TP53 and RB tumor suppressor pathways collaborate in retinoblastoma genesis].

Ayrault O, Zindy F, Roussel MF.

Med Sci (Paris). 2007 Apr;23(4):356-8. French. No abstract available.

18.

Genetic alterations in mouse medulloblastomas and generation of tumors de novo from primary cerebellar granule neuron precursors.

Zindy F, Uziel T, Ayrault O, Calabrese C, Valentine M, Rehg JE, Gilbertson RJ, Sherr CJ, Roussel MF.

Cancer Res. 2007 Mar 15;67(6):2676-84.

19.

p53-Dependent and -independent functions of the Arf tumor suppressor.

Sherr CJ, Bertwistle D, DEN Besten W, Kuo ML, Sugimoto M, Tago K, Williams RT, Zindy F, Roussel MF.

Cold Spring Harb Symp Quant Biol. 2005;70:129-37. Review.

PMID:
16869746
20.

N-Myc and the cyclin-dependent kinase inhibitors p18Ink4c and p27Kip1 coordinately regulate cerebellar development.

Zindy F, Knoepfler PS, Xie S, Sherr CJ, Eisenman RN, Roussel MF.

Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11579-83. Epub 2006 Jul 24.

21.

The CDK inhibitor p18Ink4c is a tumor suppressor in medulloblastoma.

Uziel T, Zindy F, Sherr CJ, Roussel MF.

Cell Cycle. 2006 Feb;5(4):363-5. Epub 2006 Feb 15.

PMID:
16479172
22.

Loss of p53 induces changes in the behavior of subventricular zone cells: implication for the genesis of glial tumors.

Gil-Perotin S, Marin-Husstege M, Li J, Soriano-Navarro M, Zindy F, Roussel MF, Garcia-Verdugo JM, Casaccia-Bonnefil P.

J Neurosci. 2006 Jan 25;26(4):1107-16.

23.

The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation.

Uziel T, Zindy F, Xie S, Lee Y, Forget A, Magdaleno S, Rehg JE, Calabrese C, Solecki D, Eberhart CG, Sherr SE, Plimmer S, Clifford SC, Hatten ME, McKinnon PJ, Gilbertson RJ, Curran T, Sherr CJ, Roussel MF.

Genes Dev. 2005 Nov 15;19(22):2656-67. Epub 2005 Oct 31.

24.

Tbx3, the ulnar-mammary syndrome gene, and Tbx2 interact in mammary gland development through a p19Arf/p53-independent pathway.

Jerome-Majewska LA, Jenkins GP, Ernstoff E, Zindy F, Sherr CJ, Papaioannou VE.

Dev Dyn. 2005 Dec;234(4):922-33.

25.

Arf-dependent regulation of Pdgf signaling in perivascular cells in the developing mouse eye.

Silva RL, Thornton JD, Martin AC, Rehg JE, Bertwistle D, Zindy F, Skapek SX.

EMBO J. 2005 Aug 3;24(15):2803-14. Epub 2005 Jul 21.

26.

Monoclonal antibodies to the mouse p19(Arf) tumor suppressor protein.

Bertwistle D, Zindy F, Sherr CJ, Roussel MF.

Hybrid Hybridomics. 2004 Oct;23(5):293-300.

PMID:
15672607
27.

Pathogenesis of persistent hyperplastic primary vitreous in mice lacking the arf tumor suppressor gene.

Martin AC, Thornton JD, Liu J, Wang X, Zuo J, Jablonski MM, Chaum E, Zindy F, Skapek SX.

Invest Ophthalmol Vis Sci. 2004 Oct;45(10):3387-96.

28.

Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter.

Yokota T, Matsuzaki Y, Miyazawa K, Zindy F, Roussel MF, Sakai T.

Oncogene. 2004 Jul 8;23(31):5340-9.

PMID:
15107822
29.

Arf tumor suppressor promoter monitors latent oncogenic signals in vivo.

Zindy F, Williams RT, Baudino TA, Rehg JE, Skapek SX, Cleveland JL, Roussel MF, Sherr CJ.

Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15930-5. Epub 2003 Dec 9.

30.

A molecular fingerprint for medulloblastoma.

Lee Y, Miller HL, Jensen P, Hernan R, Connelly M, Wetmore C, Zindy F, Roussel MF, Curran T, Gilbertson RJ, McKinnon PJ.

Cancer Res. 2003 Sep 1;63(17):5428-37.

31.

Hemangiosarcomas, medulloblastomas, and other tumors in Ink4c/p53-null mice.

Zindy F, Nilsson LM, Nguyen L, Meunier C, Smeyne RJ, Rehg JE, Eberhart C, Sherr CJ, Roussel MF.

Cancer Res. 2003 Sep 1;63(17):5420-7.

32.

Progressive hearing loss in mice lacking the cyclin-dependent kinase inhibitor Ink4d.

Chen P, Zindy F, Abdala C, Liu F, Li X, Roussel MF, Segil N.

Nat Cell Biol. 2003 May;5(5):422-6.

PMID:
12717441
33.

The cyclin-dependent kinase inhibitors p19(Ink4d) and p27(Kip1) are coexpressed in select retinal cells and act cooperatively to control cell cycle exit.

Cunningham JJ, Levine EM, Zindy F, Goloubeva O, Roussel MF, Smeyne RJ.

Mol Cell Neurosci. 2002 Mar;19(3):359-74.

PMID:
11906209
34.

The Arf tumor suppressor gene promotes hyaloid vascular regression during mouse eye development.

McKeller RN, Fowler JL, Cunningham JJ, Warner N, Smeyne RJ, Zindy F, Skapek SX.

Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3848-53. Epub 2002 Mar 12.

35.
36.

Differential effects of p19(Arf) and p16(Ink4a) loss on senescence of murine bone marrow-derived preB cells and macrophages.

Randle DH, Zindy F, Sherr CJ, Roussel MF.

Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9654-9. Epub 2001 Jul 31.

37.

c-Myc-mediated regulation of telomerase activity is disabled in immortalized cells.

Drissi R, Zindy F, Roussel MF, Cleveland JL.

J Biol Chem. 2001 Aug 10;276(32):29994-30001. Epub 2001 Jun 11.

38.

Control of spermatogenesis in mice by the cyclin D-dependent kinase inhibitors p18(Ink4c) and p19(Ink4d).

Zindy F, den Besten W, Chen B, Rehg JE, Latres E, Barbacid M, Pollard JW, Sherr CJ, Cohen PE, Roussel MF.

Mol Cell Biol. 2001 May;21(9):3244-55.

39.

Stat3-dependent induction of p19INK4D by IL-10 contributes to inhibition of macrophage proliferation.

O'Farrell AM, Parry DA, Zindy F, Roussel MF, Lees E, Moore KW, Mui AL.

J Immunol. 2000 May 1;164(9):4607-15.

40.

INK4d-deficient mice are fertile despite testicular atrophy.

Zindy F, van Deursen J, Grosveld G, Sherr CJ, Roussel MF.

Mol Cell Biol. 2000 Jan;20(1):372-8.

41.

Postnatal neuronal proliferation in mice lacking Ink4d and Kip1 inhibitors of cyclin-dependent kinases.

Zindy F, Cunningham JJ, Sherr CJ, Jogal S, Smeyne RJ, Roussel MF.

Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13462-7.

42.

Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled atm function.

Kamijo T, van de Kamp E, Chong MJ, Zindy F, Diehl JA, Sherr CJ, McKinnon PJ.

Cancer Res. 1999 May 15;59(10):2464-9.

43.

E1A signaling to p53 involves the p19(ARF) tumor suppressor.

de Stanchina E, McCurrach ME, Zindy F, Shieh SY, Ferbeyre G, Samuelson AV, Prives C, Roussel MF, Sherr CJ, Lowe SW.

Genes Dev. 1998 Aug 1;12(15):2434-42.

44.

Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization.

Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF.

Genes Dev. 1998 Aug 1;12(15):2424-33.

45.

Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2.

Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ.

Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8292-7.

46.

Expression of INK4 inhibitors of cyclin D-dependent kinases during mouse brain development.

Zindy F, Soares H, Herzog KH, Morgan J, Sherr CJ, Roussel MF.

Cell Growth Differ. 1997 Nov;8(11):1139-50.

47.

Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF.

Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ.

Cell. 1997 Nov 28;91(5):649-59.

48.
50.

Identification of cyclin A as a molecular target of antinuclear antibodies (ANA) in hepatic and non-hepatic autoimmune diseases.

Strassburg CP, Alex B, Zindy F, Gerken G, Lüttig B, Meyer zum Büschenfelde KH, Bréchot C, Manns MP.

J Hepatol. 1996 Dec;25(6):859-66.

PMID:
9007714

Supplemental Content

Support Center